Mode
Text Size
Log in / Sign up

Ovarian tissue cryopreservation protocols remain unstandardized for women and prepubertal girls facing gonadotoxic cancer therapiesNo universal standard exists yet for freezing ovaries before cancer treatment

AI-generated summary of the cited source, checked by automated accuracy review. How we work

Key Takeaway
Consider that OTC protocols remain variable and require optimization; differences in steps may affect tissue quality.

This systematic review evaluated the history, current procedures, and key principles of ovarian tissue cryopreservation (OTC) for women and prepubertal girls facing gonadotoxic cancer therapies. The analysis covered various techniques including slow freezing, vitrification, whole organ freezing, and nanowarming, alongside cryoprotective agents and molecular mechanisms. The review highlighted recent achievements and remaining challenges within the field.

The primary finding was that no universally standardized OTC protocols exist for slow freezing or vitrification. Differences in crucial steps, such as media composition, cryoprotectants, and the choice between slow freezing versus vitrification, may affect tissue quality and clinical outcomes. Furthermore, thawing and warming procedures are not currently standardized across practices.

Regarding emerging technologies, two promising nanowarming approaches—electromagnetic warming and photothermal heating—are currently being evaluated in animal models. The review noted that protocols remain variable and require further optimization to improve tissue and follicle viability. No data on adverse events, serious adverse events, discontinuations, or tolerability were reported in this review.

Key limitations include the variability of protocols and the need for optimization to ensure better outcomes. OTC remains the preferred fertility-preservation method for patients unable to undergo ovarian stimulation or for prepubertal girls. However, clinicians must recognize that differences in crucial steps may affect tissue quality and clinical outcomes, necessitating cautious interpretation of current practices.

For girls and women facing cancer, losing the ability to have children can feel like a second loss. Freezing ovarian tissue offers a chance to preserve fertility when standard treatments are too harsh. Yet, a recent review highlights a troubling gap: there is no agreed-upon standard for how to do this safely and effectively.

The study looked at various techniques, from slow freezing to rapid cooling methods. It found that crucial steps in the process are not standardized. Because these steps vary, the quality of the frozen tissue and the chance of a future pregnancy could change depending on the specific method used. Even thawing the tissue remains inconsistent across different centers.

New technologies like nanowarming show promise in animal studies, but human data is still missing. The review warns that until these protocols are optimized, the survival of the eggs inside the tissue is uncertain. This uncertainty is a real concern for patients counting on this option to rebuild their future.

What this means for you:
Freezing ovarian tissue helps preserve fertility, but inconsistent methods mean survival rates are not guaranteed yet.

Study Details

Study typeSystematic review
EvidenceLevel 1
PublishedMar 2026
View Original Abstract ↓
BackgroundCryopreservation is widely used across the life sciences to enable long-term storage of living cells and tissues for research or later clinical use. Its core principle is the arrest of biological activity at extremely low temperatures. Ovarian tissue cryopreservation (OTC) has become an important fertility-preserving option for women and prepubertal girls facing gonadotoxic cancer therapies.Objective and rationaleThis review summarizes the history of OTC and provides an overview of current procedures and their relevance for fertility preservation. It outlines key principles of cryopreservation, including different techniques, cryoprotective agents, molecular mechanisms, recent achievements, remaining challenges, and future perspectives. Although OTC is clinically established, protocols remain variable and require further optimization to improve tissue and follicle viability. Differences in media composition, cryoprotectants, slow freezing vs. vitrification, and thawing or warming procedures—along with ongoing debate over which technique is superior—highlight the need for research toward a standardized approach.Search methodsPubMed and MEDLINE were searched for literature published before June 2025 using the keywords cryopreservation, ovarian tissue cryopreservation (OTC), vitrification, slow freezing, nanowarming, whole organ freezing, cryoprotective agents. Reference lists were screened back to 1993. Only English-language publications were included.OutcomesThe literature review shows that no universally standardized OTC protocols exist for slow freezing or vitrification. Although both methods are routinely applied worldwide, differences in crucial steps may affect tissue quality and clinical outcomes. Thawing and warming, also essential for tissue viability, is not standardized. These findings emphasize the need for continued optimization. Research on whole-organ freezing and nanowarming is also progressing. Nanowarming aims to enable uniform warming of larger, more complex tissues, with two promising technologies—electromagnetic warming and photothermal heating—currently evaluated in animal models.Wider implicationsAs oncological treatments advance and more young female cancer patients survive, the demand for effective and standardized OTC procedures continues to grow. OTC remains the preferred fertility-preservation method for patients unable to undergo ovarian stimulation or for prepubertal girls. This review outlines current methods, highlights advances in nanowarming and whole-organ cryopreservation, and provides future perspectives for improving OTC and related technologies.
Free Newsletter

Clinical research that matters. Delivered to your inbox.

Join thousands of clinicians and researchers. No spam, unsubscribe anytime.